Predicting chemo response in bladder cancer with MRI
Part of Cancer clinical trials.
This trial uses special MRI scans to see how well bladder cancer responds to chemotherapy before surgery. It may help doctors know early if the treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bladder cancer that has not spread outside the bladder (stage cT2, cT3, or cT4).
- You are scheduled to receive cisplatin-based chemotherapy followed by surgery to remove the bladder.
- You are willing to have three MRI scans: one before chemo starts, one 24 hours after the first chemo dose, and one after chemo is complete.
- You have not had radiation therapy to the pelvic area.
- You have no severe kidney problems.
- You have not had any open or laparoscopic surgery in the pelvic area before.
- Cancer has not spread to other parts of the body (no distant metastases).
- You can safely have an MRI (no metal implants or other contraindications).
- You are able to receive cisplatin chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well MRI scans can detect bladder cancer after chemotherapy, before surgery to remove the bladder. It may help doctors know if the chemo is working.
This trial uses advanced MRI scanning to guide treatment decisions for muscle invasive bladder cancer. It aims to improve outcomes by personalizing therapy based on detailed imaging.
This trial studies how well certain markers in bladder cancer tissue can predict which patients will respond to chemotherapy given before surgery. This may help doctors choose the best treatment for each patient in the future.
This study uses a special MRI scan (mpMRI) to figure out how far suspected muscle-invasive bladder cancer has spread, using a new local staging approach. If the results are accurate, it may help doctors plan the most appropriate curative treatment sooner.
This trial uses a new technology called spatial transcriptomics to study how bladder cancer tumors respond to chemotherapy before surgery. It aims to find patterns that predict which patients will benefit from treatment.
This trial uses special MRI scans and tiny markers placed in the bladder to better plan bladder chemoradiation. The goal is to help target treatment more accurately and improve how well it can be delivered.
Hear when a new MIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.